Figure 5.

Effect of GSK343 treatment on tumor growth. Elevated nuclear pleomorphism was observed in the control group (A,A1,A2); however, GSK343 at doses of 5 mg/kg and 10 mg/kg significantly reduced it (B,B1,B2,C,C1,C2). The panels D and E showed a reduction in tumor weight and tumor burden, respectively, following GSK343 treatment at doses of 5 mg/kg and 10 mg/kg without encountering important weight differences (F). Sections were observed and photographed at 10×, 20× and 40× magnifications. Data are representative of at least three independent experiments. (D) # p < 0.05 vs. Ctr; ## p < 0.01 vs. Ctr; (E) ## p < 0.01 vs. Ctr.